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Abstract:  A first case of clinical tenofovir (TDF) HBV resistance in an HIV/HBV 
coinfected patient who developed an acute flare of hepatitis B is reported. The clinical 
course was accompanied by signs of acute liver failure after being on successful HBV 
treatment with tenofovir and persistently undetectable HBV-DNA viral load for over five 
years.  
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Case Report 
We report the case of a 44-year-old HIV/HBV co-infected homosexual patient who was on HBV 
treatment with tenofovir for over five years with HBV virus load below the detection limit. In August 
2008 he developed an acute flare of hepatitis B with signs of acute liver failure. All subsequent 
procedures described below were performed after written informed consent and in accordance with a 
positive vote by the local ethical committees. 
Chronic HBeAg-positive HBV-infection was diagnosed in 1995. He was treated with non-modified 
interferon (5x10
7U; 3x/week) for 12 months, without any response. In 1997 HIV infection was 
diagnosed with a CD4 Nadir of 280/µl. Antiretroviral therapy (ART) was initiated in 1997 combining 
zidovudine (AZT), lamivudine (3TC) and indinavir (IDV). In October 1999 the patient was referred to 
our clinic.  
Determination of HBV-DNA load revealed approximately >6xlog10 genome equivalents and an 
HIV load of 4xlog10 copies/ml, with the GPT/ALT being 45 U/L and CD4 600/µl. HBV sequence 
analysis was not performed at that time. Genotypic HIV sequencing revealed the rt-mutations M184V, 
L214F, L90M. HIV therapy was subsequently switched to abacavir (ABC), didanosine (DDI), 
stavudine (d4T) and 3TC leading to a drop of HIV titer below 50 copies/ml. 
An acute toxic hepatitis (Figure 1) due to abuse of anabolic steroids necessitated an interruption of 
ART in 06/2001 and resulted in an increase of HIV viral load (Figure 2). In 09/2002 ART was 
resumed with the combination of tenofovir, DDI, ABC and efavirenz (EFV). During the next years, 
HBV-titer declined below the detection level (04/2003: <1000 copies/ml; 10/2003: 8000c/ml; 02/2004: 
4000c/ml; 08/2004: 5000c/ml; 04/2005: 1000c/ml; 10/2005: <100c/ml; 11/2006: <70c/ml;   
03/2007: <70c/ml). 
In 2004 hypertension was diagnosed and treated with ramipril and hydrochlorothiazide. Acute 
myocardial infarction with cardiac arrest and emergency stenting of the left main coronary artery 
occurred in January 2008. Coronary artery disease and cardiac insufficiency with an ejection fraction 
of 25% was treated with clopidogrel, acetyl salicylic acid (ASS), carvedilol, ramipril, torasemid and 
simvastatin. In response to the publication of D:A:D cohort data showing an increased risk of 
myocardial infarction in patients treated with DDI and ABC, the latter drugs were discontinued in June 
2008 and the ART regimen was switched to Emtricitabine (FTC), AZT, TDF and EFV [1]. The patient 
did not show up for scheduled laboratory examinations in 07/2008. In 08/2008 clinically severe acute 
hepatitis with signs of liver failure developed (ALT 3.060 U/l, AST 3004 U/l, AP 189 U/l, Bilirubin 24 
mg/dl, INR 1,59, and (Pseudo-)Cholinesterase/CHE 4060 U/l). At this time HBV-load increased to 
200.000 IU/ml (approx. 1x10
7 c/mL). Abuse of illicit drugs, herbal medications or anabolic steroids 
was not recorded. Autoimmune hepatitis, Wilson’s disease, Hemochromatosis, acute viral hepatitis 
A/C/D/E were excluded by laboratory examinations. The patient was admitted to the hospital for 
impending liver failure. Liver biopsy revealed expanded lymphocytic portal-lobular inflammation with 
necrosis and apoptotic areas, multifocal border zone activity, portal fibrosis and 30% fatty parenchyma 
that was suspected to have a toxic component. Concerns of possible drug toxicity led to the 
discontinuation of simvastatin, clopidogrel, and FTC. Meanwhile Entecavir was added to the regimen 
and led to a rapid decline of HBV viremia, improvement of liver function tests and clinical symptoms 
(Figure 1). HBV-DNA became undetectable in 01/2009 and transaminases returned to normal levels in Viruses 2010, 2                                       
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05/2009. Analysis of stored frozen plasma samples revealed HBV titer of 9.800.000 U/ml in 08/2007, 
20.000 U/ml in 11/2007 and 4.200 U/ml in 05/2008. In 11/2007 serum transaminases were elevated for 
the first time since 04/2005 (ALT: 80 U/l, AST: 53 U/l).  
Figure 1. Fluctuation of liver enzymes throughout the whole observation period (IU/ml). 
GPT = ALT, GOT = AST. 
 
At the time of the flare in 08/2008 sequencing of the HBV polymerase was performed in three 
independent laboratories with identical results. The patient is infected with an HBV genotype A 
(99.8% similarity). Although the patient was continuously treated with TDF+FTC, no mutations 
known or suspected to contribute to TDF/3TC/FTC resistance were found except polymorphisms 
rtL217R and rtS219A. However, none of them are mediating or associated with TDF resistance [2,3,4].  
Despite the lack of mutations leading to tenofovir (TDF) resistance, the patient suffered from 
clinical resistance to anti-HBV therapy. HBV DNA levels fluctuated strongly despite continuous 
treatment with TDF over one year with minimal increases in transaminases (1-2 times the upper limit 
of normal). Analysis of 165 HIV/HBV-coinfected patients in France showed that clinical resistance to 
tenofovir occurred only in two cases, both of them infected with HBV genotype A [5]. Here, 
previously undescribed R274W and S219A mutations were found, but no A194T mutation was 
detected. As a matter of speculation, however, those mutations or hitherto un-observed mutations Viruses 2010, 2                                       
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located in the periphery of the putative active domain of the viral reverse transcriptase may be 
responsible for the virological breakthrough, highlighting the need for systematic analyses of the 
whole viral polymerase gene in case of resistance [1-17]. As long as no crystal structure of the 
molecule exists computer assisted models may be a good approximation in the prediction of the 
resistance profile when a given mutation occurs. 
Figure 2. Course of viremia of both HIV-RNA and HBV-DNA (genome copies per ml 
plasma) throughout the observation period. 3TC: Lamivudine; TI: Treatment Interruption; 
TDF: Tenofovir; FTC: Emtricitabine; ETV: Entecavir. 
 
 
The HIV load during the HBV flare remained below 50 copies/ml, thus clearly proving the patients’ 
adherence to antiviral therapy particularly accounting for the low genetic barrier of an efavirenz based 
antiretroviral regimen. Nevertheless, although general lack of treatment adherence is most unlikely in Viruses 2010, 2                                       
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view of HIV viremia remaining suppressed, it cannot be fully ruled out that the patient was not fully 
adherent to TDF. In this context extremely high HBV load of 9.800.000 U/ml in 08/2007 is intriguing 
and a measurement of the TDF drugs levels should have occurred to fully exclude any lack of 
compliance. Since some rt217R variant HBV-strains remain susceptible to antiviral therapy, it is rather 
unlikely that this mutation alone accounts for the observed clinical resistance. It appears likely that 
resistance to antiviral therapy in HBV infected patients is due to – so far unknown - host mechanisms 
[17]. In conjunction with pre-existing liver damage components of the complex antiretroviral and 
cardiovascular drug regimen may have contributed to liver dysfunction which in turn led to the clinical 
picture of acute liver failure in our patient.  
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